Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action

Journal of Medicinal Chemistry

Volumn 39, Issue 13, 1996, Pages 2594-2608

  Fournie Zaluski, Marie Claude ^a   Coric, Pascale ^a   Thery, Vincent ^a   Gonzalez, Walter ^b   Meudal, Hervé ^a   Turcaud, Serge ^a   Michel, Jean Baptiste ^b   Roques, Bernard P ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 3 (2 MERCAPTO 3 PHENYLPROPIONAMIDO) 2 OXO 1H BENZAZEPINE 1 ACETIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; BMS 182657; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; RB 106; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HYPERTENSION; MOLECULAR MODEL; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIPEPTIDES; DRUG DESIGN; KIDNEY; LUNG; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MODELS, CHEMICAL; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NEPRILYSIN; PROTEASE INHIBITORS; RABBITS; RATS; TESTIS;

EID: 0029971125     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950783c     Document Type: Article

References (70)

1. Ames, R. P.; Borkowski, A. J.; Sicinski, A. M.; Laragh, J. H. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance and aldosterone and cortisol secretion in man and in cirrhosis with ascites. J. Clin. Invest. 1965, 44, 1171-1186.
2. Brenner, B. M.; Ballermann, B. J.; Gunning, M. E.; Zeidel, M. L. Diverse biological actions of atrial natriuretic peptide. Physiol. Rev. 1990, 70, 665-690.
3. Kenny, A. J.; Stephenson, S. L. Role of endogenous 24.11 in inactivation of atrial natriuretic peptide. FEBS Lett. 1988, 232, 507-513.
4. Erdos, E. G.; Skidgel, R. A. Structure and function of human angiotensin I converting enzyme. Biochem. Soc. Trans. 1985, 13, 42-44.
5. Ura, N.; Carretero, O. A.; Erdos, E. G. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 1987, 32, 507-513.
6. Wyvratt, M. J.; Patchett, A. A. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med. Res. Rev. 1985, 5, 483-531. (This review contains several references to ACE inhibitors containing phenyl-substituted proline or 2-phenyl-4-thiazolidinecarboxylic acid.)
7. Lawton, G.; Pacioreck, P. M.; Waterfall, J. F. The design and biological profile of ACE inhibitors. Advances in Drug Research; Harcourt Brace Jovanovich: London, 1992; Vol. 23, pp 161-220.
8. Roques, B. P.; Noble, F.; Daugé, V.; Fournié-Zaluski, M. C.; Beaumont, A. Neutral endopeptidase 24.11: structure, inhibition and experimental and clinical pharmacology. Pharmacol. Rev. 1993, 45, 87-146.
9. Seymour, A. A.; Fennell, S. A.; Swerdel, J. N. Potentiation of renal effects of atrial natriuretic factor (99-126) by SQ-29,072. Hypertension 1989, 14, 87-97.
10. Sybertz, E. J.; Chiu, P. J. S.; Vemulapalli, S.; Watkins, R.; Haslanger, M. F. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH-34,826. An orally active neutral metalloendopeptidase inhibitor. Hypertension 1990, 15, 152-161.
11. Hirata, Y.; Matsuoka, H.; Hayakawa, H.; Sugimoto, T.; Suzuki, E.; Sugimoto, T.; Kasigawa, K.; Matsuo, M. Role of endogenous atrial natriuretic peptide in regulating sodium extraction in spontaneously hypertensive rats. Effects of neutral endopeptidase inhibition. Hypertension 1990, 17, 1025-1032.
12. Bralet, J.; Mossiat, C.; Lecomte, J. M.; Charpentier, S.; Gros, C.; Schwartz, J. C. Diuretic and natriuretic responses in rate treated with enkephalinase inhibitors. Eur. J. Pharmacol. 1990, 179, 57-64.
13. Seymour, A. A.; Norman, J. A.; Asaad, M. M.; Fennell, S. A.; Little, D. K.; Kratunis, V. J.; Rogers, W. L. Antihypertensive and renal activity of SQ-28,603 on inhibitor of neutral endopeptidase. J. Cardiovasc. Pharmacol. 1991, 17, 296-304.
14. Pham, I.; El Amrani, A. I. K.; Fournié-Zaluski, M. C.; Corvol, P.; Roques, B. P.; Michel, J. B. Effects of the selective neutral endopeptidase inhibitor retrothiorphan on renal function and blood pressure in normotensive and in DOCA-salt hypertensive rats. J. Cardiovasc. Pharmacol. 1992, 20, 847-857.
15. Sybertz, E. J.; Chiu, P. J. S.; Vemulapalli, S.; Pitts, B.; Foster, C. J.; Watkins, R. W.; Barnett, M.; Haslanger, M. F. SCH-39,370, a neutral metalloendopeptidase inhibitor potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone-acetate-sodium hypertensive rats. J. Pharmacol. Exp. Ther. 1989, 250, 624-631.
16. Seymour, A. A.; Norman, J. A.; Asaad, M. M.; Fennell, S. A.; Abboa-Offei, B.; Little, D. K.; Kratunis, V. J.; Delaney, N. G.; Hunt, J. T.; Di Donato, G. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors. J. Pharmacol. Exp. Ther. 1991, 256, 1002-1009.
17. Northridge, D. B.; Jardine, A. G.; Findlay, I. N.; Archibald, M.; Dilly, S. G.; Dargie, H. J. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am. J. Hypertens. 1990, 3, 682-687.
18. Kromer, E. P.; Elsner, D.; Kahles, H. W.; Riegger, C. A. Effects of atriopeptidase inhibitor UK-79,300 on left ventricular hydraulic load in patients with congestive heart failure. Am. J. Hypertens. 1991, 4, 460-463.
19. Roques, B. P.; Beaumont, A. Neutral endopeptidase 24.11 inhibitors: from analgesia to antihypertensive? Trends Pharmacol. Sci. 1990, 11, 245-249.
20. Seymour, A. A.; Swerdel, J. N.; Abboa-Offei, B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J. Cardiovasc. Pharmacol. 1991, 17, 456-465.
21. Pham, I.; Gonzalez, W.; El Amrani, A. I. K.; Fournié-Zaluski, M. C.; Philippe, M.; Laboulandine, I.; Roques, B. P.; Michel, J. B. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J. Pharmacol. Exp. Ther. 1993, 265, 1339-1347.
22. Seymour, A. A.; Asaad, M. M.; Lanoce, V. M.; Langenbacher, K. M.; Fennell, S. A.; Rogers, W. L. Systemic hemodynamics renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme in conscious dogs with pacing-induced heart failure. J. Pharmacol. Exp. Ther. 1993, 266, 872-883.
23. Trippodo, N. C.; Fox, M.; Natarajan, V.; Panchal, B. C.; Dorso, C. R.; Asaad, M. M. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J. Pharmacol. Exp. Ther. 1993, 267, 108-116.
24. (a) Stanton, J. L.; Sperbeck, D. M.; Trapani, A. J.; Cote, D.; Sakane, Y.; Berry, C. J.; Ghai, R. D. Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors. J. Med. Chem. 1993, 36, 3829-3833.
25. (b) Robl, J. A.; Simpkins, L. M.; Stevenson, J.; Sun, C.-Q.; Murugesan, N.; Barrish, J. C.; Asaad, M. M.; Bird, J. E.; Schaeffer, T. R.; Trippodo, N. C.; Petrillo, E. W.; Karanewsky, D. S. Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptides. Bioorg. Med. Chem. Lett. 1994, 4 (15), 1789-1794.
26. (c) Robl, J. A.; Simpkins, L. M.; Sulsky, R.; Sieber-McMaster, E.; Stevenson, J.; Kelly, Y. F.; Sun, C.-Q.; Misra, R. N.; Ryono, D. E.; Asaad, M. M.; Bird, J. E.; Trippodo, N. C.; Karanewsky, D. S. Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls. Bioorg. Med. Chem. Lett. 1994, 4 (15), 1795-1800.
27. (d) Robl, J. A.; Sun, C.-Q.; Simpkins, L. M.; Ryono, D. E.; Barrish, J. C.; Karanewsky, D. S.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors. III. Utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls. Bioorg. Med. Chem. Lett. 1994, 4 (16), 2055-2060.
28. (e) Das, J.; Robl, J. A.; Reid, J. A.; Sun, C.-Q.; Misra, R. N.; Brown, B. R.; Ryono, D. E.; Asaad, M. M.; Bird, J. E.; Trippodo, N. C.; Petrillo, E. W.; Karanewsky, D. S. Dual metalloprotease inhibitors. IV. Utilization of thiazepines and thiazines as constrained peptidomimetic surrogates in mercaptoacyl dipeptides. Bioorg. Med. Chem. Lett. 1994, 4 (18), 2193-2198.
29. (f) Slusarchyk, W. A.; Robl, J. A.; Taunk, P. C.; Asaad, M. M.; Bird, J. E.; DiMarco, J.; Pan, Y. Dual metalloprotease inhibitors. V. Utilization of bicyclic azepinonethiazolidines and azepinonetetrahydrothiazines in constrained peptidomimetics of mercaptoacyl dipeptides. Bioorg. Med. Chem. Lett. 1995, 5 (7), 753-758.
30. (g) Bhagwat, S. S.; Fink, C. A.; Gude, C.; Chan, K.; Qiao, Y.; Sakane, Y.; Berry, C.; Ghai, R. D. 4-substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase. Bioorg. Med. Chem. Lett. 1994, 4, 2673-2676.
31. Fournié-Zaluski, M. C.; Llorens, C.; Gacel, G.; Malfroy, B.; Swerts, J. P.; Lecomte, J. M.; Schwartz, J. C.; Roques, B. P. Synthesis and biological properties of highly potent enkephalinase inhibitors. In Peptides 1980, Proc. of the Sixteenth European Symposium; Brunfeld, K., Ed.; Scriptor: Copenhagen, 1981; pp 476-481.
32. Gordon, E. M.; Cushman, D. W.; Tung, R.; Cheung, M. S.; Wang, F. L.; Delaney, N. G. Rat brain enkephalinase: characterization of the active site using mercaptopropanoyl amino acid inhibitors and comparison with angiotensin converting enzyme. Life Sci. 1983, 33 (Suppl. 1), 113-116.
33. Fournié-Zaluski, M. C.; Lucas, E.; Waksman, G.; Roques, B. P. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin converting enzyme, molecular investigation by use of new thiol inhibitors. Eur. J. Biochem. 1984, 139, 267-274.
34. Roques, B. P.; Fournié-Zaluski, M. C.; Soroca, E.; Lecomte, J. M.; Malfroy, B.; Llorens, C.; Schwartz, J. C. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature (London) 1980, 288, 286-288.
35. Gros, C.; Noel, N.; Souque, A.; Schwartz, J. C.; Danvy, D.; Plaquevent, J. C.; Duhamel, L.; Duhamel, P.; Lecomte, J. M.; Bralet, J. Mixed inhibitors of angiotensin converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties and potential cardiovascular applications of glycopril and alatriopril. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 4210-4214.
36. Fournie-Zaluski, M. C.; Coric, P.; Turcaud, S.; Rousselet, N.; Gonzalez, W.; Barbe, B.; Pham, I.; Jullian, N.; Michel, J. B.; Roques, B. P. New dual inhibitors of neutral endopeptidase and angiotensin converting enzyme: rational design, bioavailability and pharmacological responses on experimental hypertension. J. Med. Chem. 1994, 37, 1070-1083.
37. Fournié-Zaluski, M. C.; Gonzalez, W.; Turcaud, S.; Pham, I.; Roques, B. P.; Michel, J. B. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril I: a new therapeutic approach in hypertension. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4072-4076.
38. Gonzalez-Vera, W.; Fournié-Zaluski, M. C.; Pham, I.; Laboulandine, I.; Beslot, F.; Roques, B. P.; Michel, J. B. Hypotensive and natriuretic effects in hypertensive rats of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J. Pharmacol. Exp. Ther. 1995, 272, 343-351.
39. French, J. F.; Flynn, G. A.; Giroux, E. L.; Mehdi, S.; Anderson, B.; Beach, D. C.; Koehl, J. R.; Dage, R. C. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J. Pharmacol. Exp. Ther. 1994, 288, 180-186.
40. French, J. F.; Anderson, B. A.; Downs, T. R.; Dage, R. C. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase in rats with hypertension. J. Cardiovasc. Pharmacol. 1995, 26, 107-113.
41. Piedimonte, G.; Nadel, J. A.; Long, C. S.; Hoffman, J. I. E. Neutral endopeptidase in the heart: neutral endopeptidase inhibitions prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ. Res. 1994, 75, 770-779.
42. Coric, P.; Turcaud, S.; Meudal, H.; Roques, B. P.; Fournié-Zaluski, M. C. Differences in optimal recognition of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) actives sites by mercaptoacyldipeptides. A new approach in the design of potent dual inhibitors. J. Med. Chem. 1996, 39, 1210-1219.
43. Gomez-Monterrey, I.; Beaumont, A.; Roques, B. P.; Fournié-Zaluski, M. C. New thiol inhibitors of neutral endopeptidase E. C. 24.11: synthesis and enzyme active-site recognition. J. Med. Chem. 1994, 37, 1865-1873.
44. Gomez-Monterrey, I.; Turcaud, S.; Lucas, E.; Bruetschy, L.; Roques, B. P.; Fournié-Zaluski, M. C. Exploration of neutral endopeptidase (EC 3.4.24.11.) active site by a series of new thiol containing inhibitors. J. Med. Chem. 1993, 36, 87-94.
45. Pascard, C.; Guilhem, J.; Vincent, M.; Remond, G.; Portevin, B.; Laubie, M. Configuration and preferential solid state conformations of perindoprilate (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure activity relationships. J. Med. Chem. 1991, 34, 663-669.
46. Cushman, D. W.; Cheung, H. S.; Sabo, E. F.; Ondetti, M. A. Design of potent competitive inhibitors of angiotensin converting enzyme. Carboxy alkanoyl and mercapto alkanoylamino acids. Biochemistry 1977, 16, 5484-5491.
47. Ohta, T.; Hosoi, A.; Kimura, T.; Nozoe, S. Direct chain elongation of N-carbamoylpyroglutamate. An efficient synthesis of (-)-pyrrolidine-2,5-dicarboxylic acid. Chem. Lett. 1987, 2091-2094.
48. Ezquerra, J.; Pedregal, C.; Rubio, A.; Valenciano, J.; Navio, J. L. G.; Alvarez-Builla, J.; Vaquero, J. J. General method for the synthesis of 5-arylpyrrole-2-carboxylic acids. Tetrahedron Lett. 1993, 34, 6317-6320.
49. Overberger, C. G.; David, K. H.; Moore, J. A. Synthesis and resolution of cis and trans 5-methylproline. Macromolecules 1972, 5, 368-372.
50. Aubry, M.; Bertheloot, A.; Beaumont, A.; Roques, B. P.; Crine, P. The use of a monoclonal antibody for the high yield purification of kidney enkephalinase solubilized in β octyl glucoside. Biochem. Cell. Biol. 1987, 65, 398-404.
51. Pantaliano, M. W.; Holmquist, B.; Riordan, J. F. Affinity chromatographic purification of angiotensin converting enzyme. Biochemistry 1984, 23, 1037-1042.
52. Benchetrit, T.; Fournié-Zaluski, M. C.; Roques, B. P. Relationship between the inhibitory potencies of thiorphan and retrothiorphan enantiomers on thermolysin and neutral endopeptidase 24.11 and their interactions with the thermolysin active site by computer modeling. Biochem. Biophys. Res. Commun. 1987, 147, 1034-1040.
53. Wattley, J. W. M.; Gavin, T.; Desai, M. Bicyclic lactam inhibitors of angiotensin converting enzyme. J. Med. Chem. 1984, 27, 816-818.
54. Andrews, P. R.; Carson, J. M.; Caselli, A.; Spark, M. J.; Woods, R. Conformational analysis and active site modeling of angiotensin converting enzyme inhibitors. J. Med. Chem. 1985, 28, 393-399.
55. Roderick, S. L.; Fournié-Zaluski, M. C.; Roques, B. P.; Matthews, B. W. Thiorphan and retrothiorphan display equivalent interactions when bound to crystalline thermolysin. Biochemistry 1989, 28, 1493-1497.
56. Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hakes, P. W.; Dage, R. C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2423.
57. Benchetrit, T.; Bissery, V.; Mornon, J. P.; Devault, A.; Crine, P.; Roques, B. P. Primary structure homologies between two zinc-metallopeptidases, the neutral endopeptidase 24.11 "enkephalinase" and the thermolysin through clustering. Biochemistry 1988, 27, 592-596.
58. Soleilhac, J. M.; Lucas, E.; Beaumont, A.; Turcaud, S.; Michel, J. B.; Ficheux, D.; Fournié-Zaluski, M. C.; Roques, B. P. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol. Pharmacol. 1992, 41, 609-614.
59. O'Donnell, M. J.; Eckrich, T. M. The synthesis of amino acid derivatives by catalytic phase transfer alkylations. Tetrahedron Lett. 1978, 4625-4628.
60. Winkle, M. R.; Ronald, R. C. Regioselective metalation reactions of some substituted (methoxymethoxy) arenes. J. Org. Chem. 1982, 47, 2101-2108.
61. Koga, K.; Juang, T. M.; Yamada, S. Stereochemical studies L II Studies on the stereochemical courses in deaminative bromination of 3,5-dichloro-L-tyrosine and in animation of the corresponding α-bromo acid. Existence of strong neighboring phenoxide group participation. Chem. Pharm. Bull. 1978, 26, 178-184.
62. 2. Biopolymers 1994, 34, 155-169.
63. Hagler, A. T. Theoretical simulation of conformation, energetics and dynamics of peptides. In The Peptides: Conformations in Biology and Drug Design; Hruby, V. J., Meienhofer, J., Eds.; Academic Press: New York, 1985; pp 213-299.
64. Dauber-Osgerthorpe, P.; Roberts, V. A.; Osgerthorpe, D. J.; Woff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: E-Coli dihydrofolate reductase-trimethoprim, a drug receptor system. Proteins 1988, 4, 31-47.
65. Piquilloud, Y.; Reinharz, A.; Roth, M. Studies of the angiotensin converting enzyme with different substrats. Biochim. Biophys. Acta 1970, 206, 136-142.
66. Llorens, C.; Malfroy, B.; Schwartz, J. C.; Gacel, G.; Roques, B. P.; Roy, J.; Morgat, J. L.; Javoy-Agid, F. Enkephalin dipeptidyl carboxypeptidase (enkephalinase): selective radioassay, properties and regional distribution in human brain. J. Neurochem. 1982, 39, 1081-1089.
67. Vogel, Z.; Altstein, M. The adsorption of enkephalin to porous polysterene beads: a simple assay for enkephalin hydrolysis. FEBS Lett. 1977, 80, 332-336.
68. Benchetrit, T.; Fournié-Zaluski, M. C.; Roques, B. P. Relationship between the inhibitory potencies of thiorphan and retrothiorphan enantiomers on thermolysin and neutral endopeptidase 24.11 and their interactions with the thermolysin active site by computer modeling. Biochem. Biophys. Res. Commun. 1987, 147, 1034-1040.
69. Cheung, H. S.; Cushman, D. W. Inhibition of homogenous angiotensin converting enzyme of rabbit lung by synthetic venom peptides of bothrops Jararaca. Biochim. Biophys. Acta 1973, 293, 451-457.
70. Seymour, A. A.; Asaad, M. M.; Abboa-Offei, B. E.; Smith, P. L.; Rogers, W. L.; Dorso, C. R. Determinants of in vivo activity of neutral endopeptidaae 3.4.24.11 and angiotensin converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 1996, 276, 708-713.